Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult...
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
Polivy (polatuzumab vedotin) for the Treatment of Diffuse Large B-cell Lymphoma
Polivy™ (polatuzumab vedotin-piiq) is an antibody-drug conjugate indicated for the third-line treatment of adults with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Zolgensma for the Treatment of Spinal Muscular Atrophy
Zolgensma® (onasemnogene abeparvovec-xioi) is a gene replacement therapy indicated for the treatment of spinal muscular atrophy (SMA) in paediatric patients.
Quick and Flexible Elemental Screening with Omnian
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis
Skyrizi™ (risankizumab-rzaa) is a monoclonal antibody (mAb) indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients.
Dovato (dolutegravir/lamivudine) for the Treatment of HIV Infection
Dovato® (dolutegravir/lamivudine) is a two-drug regimen indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.